SCHEMBL30476445

SCHEMBL30476445

CCC(c1cccnc1)N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.58
CYP3A5 P20815 3/20 0.58
GPR119 Q8TDV5 1/20 0.51
PLA2G7 Q13093 1/20 0.51
MGLL Q99685 1/20 0.51
ABHD6 Q9BV23 1/20 0.51
TP53 P04637 1/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HSD17B10 Q99714 1/20 0.47
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
ALOX12 P18054 1/20 0.46
MPI P34949 1/20 0.46
ESR2 Q92731 1/20 0.46
GAA P10253 1/20 0.46
GBA1 P04062 1/20 0.46
TSHR P16473 1/20 0.46
MEN1 O00255 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20818634 1.00 CYP3A4 (0.58) CYP3A4CYP3A5GPR119PLA2G7MGLL
SCHEMBL14035283 0.91 CYP3A4 (0.58) CYP3A4CYP3A5GPR119PLA2G7MGLL
SCHEMBL15093706 0.86 CYP3A4 (0.71) CYP3A4CYP3A5GPR119PLA2G7MGLL
SCHEMBL31071488 0.86 CYP3A4 (0.71) CYP3A4CYP3A5GPR119PLA2G7MGLL
SCHEMBL38661641 0.86 GPR119 (0.49) CYP3A4CYP3A5GPR119ALDH1A1MAPT
SCHEMBL7985622 0.86 GAA (0.50) GPR119MGLLKDM4EALDH1A1MAPT
SCHEMBL210120 0.85 CYP3A4 (0.61) CYP3A4CYP3A5GPR119PLA2G7MGLL
SCHEMBL25241482 0.83 TP53 (0.52) CYP3A4CYP3A5TP53KDM4EALDH1A1
SCHEMBL19668681 0.83 CYP3A4 (0.59) CYP3A4CYP3A5GPR119PLA2G7MGLL
SCHEMBL29363322 0.83 CYP3A4 (0.59) CYP3A4CYP3A5GPR119PLA2G7MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF PDXK, ATP6V1B1, REN CYP3A4 101/4885CYP3A5 53/4885GPR119 846/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN CYP3A4 101/4885CYP3A5 53/4885GPR119 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.